ArticleJIMD reports2012
Successful weight loss in two adult patients diagnosed with late-onset long-chain Fatty Acid oxidation defect.
Article in JIMD reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Central administration of docosahexaenoic acid, eicosapentaenoic acid, or linoleic acid activates hypothalamic fatty acid sensing and is involved in reproductive regulation in spotted scat (Scatophagus argus).Fish physiology and biochemistry · 2025Article
- Dietary restriction in the long-chain acyl-CoA dehydrogenase knockout mouse.Molecular genetics and metabolism reports · 2021Article
- Clinical manifestations and management of fatty acid oxidation disorders.Reviews in endocrine & metabolic disorders · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledPatients with long-chain fatty acid oxidation defect (LCFAOD) cannot tolerate fasting and are restricted in their physical activity, hence their increased risk of obesity. Experts therefore advise avoidance of catabolic situations and discourage weight reduction in these patients.Two patients with late-diagnosed LCFAOD undergoing treatment at two academic centers successfully lost weight under supervision of a metabolic dietitian. Patient 1 (male, 47 years) diagnosed with CPT 2 deficiency lost 10 kg body weight in a 3-month period with the help of an energy and LCT-restricted, MCT- and carbohydrate-rich diet in combination with an exercise program. CK levels, C16, C18, and C18:1 levels of his acylcarnitine profile and his blood pressure decreased during the period of weight reduction. Patient 2 (male, 39 years) has a VLCAD deficiency. Dietary advice was energy and LCT restriction, MCT and carbohydrate-enriched food with raw cornstarch added during the night. Patient 2 lost almost 40 kg body weight to 87.6 kg (BMI 25.1) in 2 years. CK, insulin, TG, and ALAT blood levels decreased.
conclusionWeight reduction without loss of metabolic control seems possible in late-onset LCFAOD patients. No metabolic crisis occurred in these two patients, while the positive effects of weight reduction were clear. The residual enzyme function in late-onset LCFAOD may be one of the reasons that metabolic decompensation was prevented. In addition, dietary adjustments to prevent excessive fatty acid oxidation likely contributed as well. Therefore, expert supervision by a dietician specialized in metabolic diseases is recommended. Concise SentenceContrary to the current literature, weight loss in patients with late-diagnosed LCFAOD can be successful. A description of two FOAD patients who lost weight without encountering negative side effects at two academic centers is given.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.